Business Context and Reporting Period
This Form 8-K Current Report was filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on February 16, 2021. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 46,875,000 shares of common stock at a public offering price of $1.60 per share.
- Gross Proceeds: Approximately $75,000,000 before underwriting discounts, commissions, and estimated offering expenses.
- Over-Allotment Option: The underwriter (H.C. Wainwright & Co., LLC) was granted an option to purchase up to an additional 7,031,250 shares within 30 days.
- Underwriter Warrants: The company issued warrants to purchase up to 3,750,000 shares (8% of shares sold) at an exercise price of $2.00 per share, exercisable for five years.
- Use of Proceeds: Primarily for working capital and general corporate purposes.
- Expected Closing Date: On or about February 19, 2021.
Material Changes and Agreements
The primary material change is the execution of an amended and restated underwriting agreement. This transaction represents a significant capital raise event. Additionally, certain officers and directors entered into "lock-up" agreements prohibiting the sale of securities for 30 days from the agreement date. The offering was made pursuant to an effective shelf registration statement (Form S-3) filed in May 2020.
Outlook, Risks, and Contingencies
The filing contains forward-looking statements regarding the anticipated closing of the offering and expected proceeds. Management cautions that these statements are subject to risks and uncertainties, including the company's ability to satisfy closing conditions on a timely basis or at all. The filing explicitly states that the company does not intend to revise or update forward-looking statements to reflect future events except as required by law.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and expenses.
- Confirm whether the underwriter exercised the over-allotment option for the additional 7,031,250 shares.
- Review the prospectus supplement filed on February 18, 2021, for detailed risk factors and use of proceeds.
- Monitor the company's cash position post-closing to assess the impact on working capital.
- Note the potential future dilution from the 3,750,000 underwriter warrants exercisable at $2.00 per share.